Serial electrophysiologic studies of the effects of oral diltiazem on paroxysmal supraventricular tachycardia.
In 16 patients with paroxysmal supraventricular tachycardia, electrophysiologic studies were done before and serially at hourly intervals for eight hours after the third oral dose of 90 mg diltiazem given every eight hours. Diltiazem increased both the longest atrial paced cycle length producing type 1 atrioventricular block and the effective refractory period of the atrioventricular conducting system at all measurements. Before diltiazem, all 16 patients had induction of sustained tachycardia. After diltiazem, sustained tachycardia could not be induced in ten patients at any measurements; in these patients, either echo or nonsustained tachycardia was induced. In the remaining six patients, sustained tachycardia was induced, particularly after six hours. Follow-up observations in 12 patients receiving the same dosage of oral diltiazem for 6 +/- 2 months (mean +/- SD), showed that of the eight patients in whom electrophysiologic testing induced either echo or nonsustained tachycardia, six were asymptomatic and two experienced transient palpitation. Of the other four patients with induction of sustained tachycardia, three had transient palpitation and one had occasional attacks of sustained tachycardia requiring modification of therapy. Thus, oral diltiazem increases atrioventricular nodal refractoriness, with an effect lasting up to eight hours. It is an effective agent for the prophylaxis of paroxysmal supraventricular tachycardia.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001283:Atrioventricular Node / Q000187:drug effects / Q000503:physiopathology*; D001552:Benzazepines / Q000494:pharmacology*; D001794:Blood Pressure; D004110:Diltiazem / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D005260:Female; D006329:Heart Conduction System / Q000503:physiopathology*; D006339:Heart Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D009431:Neural Conduction / Q000187:drug effects*; D012032:Refractory Period, Electrophysiological / Q000187:drug effects*; D013614:Tachycardia, Paroxysmal / Q000097:blood / Q000503:physiopathology* / Q000517:prevention & control; D014927:Wolff-Parkinson-White Syndrome / Q000503:physiopathology
D001552:Benzazepines; D004110:Diltiazem